CL2021002013A1 - Biomarcadores para el diagnóstico de cáncer de ovario - Google Patents
Biomarcadores para el diagnóstico de cáncer de ovarioInfo
- Publication number
- CL2021002013A1 CL2021002013A1 CL2021002013A CL2021002013A CL2021002013A1 CL 2021002013 A1 CL2021002013 A1 CL 2021002013A1 CL 2021002013 A CL2021002013 A CL 2021002013A CL 2021002013 A CL2021002013 A CL 2021002013A CL 2021002013 A1 CL2021002013 A1 CL 2021002013A1
- Authority
- CL
- Chile
- Prior art keywords
- biomarkers
- glycopeptide
- diagnosis
- methods
- ovarian cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N3/00—Computing arrangements based on biological models
- G06N3/02—Neural networks
- G06N3/08—Learning methods
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/26—Mass spectrometers or separator tubes
- H01J49/34—Dynamic spectrometers
- H01J49/40—Time-of-flight spectrometers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Data Mining & Analysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Artificial Intelligence (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Organic Chemistry (AREA)
- Mathematical Physics (AREA)
- Bioethics (AREA)
Abstract
En la presente se establecen biomarcadores de glicopéptidos útiles para el diagnóstico de enfermedades y afecciones, tales como, de modo no taxativo, el cáncer (por ejemplo, de ovario), una enfermedad autoinmunitaria, fibrosis y afecciones por envejecimiento. También se establecen en la presente métodos de generación de biomarcadores de glicopéptidos y métodos de análisis de glicopéptidos mediante espectroscopía un péptido o glicopéptido que consiste a de masas. También se establecen en la presente métodos de análisis de glicopéptidos mediante algoritmos de aprendizaje automático.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962800323P | 2019-02-01 | 2019-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002013A1 true CL2021002013A1 (es) | 2022-01-21 |
Family
ID=69771064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002013A CL2021002013A1 (es) | 2019-02-01 | 2021-07-30 | Biomarcadores para el diagnóstico de cáncer de ovario |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220139499A1 (es) |
EP (1) | EP3918334A1 (es) |
JP (1) | JP7493815B2 (es) |
KR (1) | KR20210124269A (es) |
CN (1) | CN113439213A (es) |
AU (1) | AU2020216996A1 (es) |
BR (1) | BR112021014978A2 (es) |
CA (1) | CA3128367A1 (es) |
CL (1) | CL2021002013A1 (es) |
IL (1) | IL285218A (es) |
SG (1) | SG11202108327VA (es) |
WO (1) | WO2020160515A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11592448B2 (en) * | 2017-06-14 | 2023-02-28 | Discerndx, Inc. | Tandem identification engine |
EP3676393A4 (en) | 2017-09-01 | 2021-10-13 | Venn Biosciences Corporation | IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT |
KR20210145210A (ko) | 2019-03-29 | 2021-12-01 | 벤 바이오사이언시스 코포레이션 | 질량 분석 데이터의 경계 자동 검출 |
JP7380515B2 (ja) * | 2020-10-19 | 2023-11-15 | 株式会社島津製作所 | 質量分析を用いた試料分析方法及び試料分析システム |
EP4305427A1 (en) * | 2021-03-08 | 2024-01-17 | Venn Biosciences Corporation | Biomarkers for determining an immuno-oncology response |
AU2022276734A1 (en) * | 2021-05-18 | 2024-01-04 | Venn Biosciences Corporation | Biomarkers for diagnosing ovarian cancer |
KR20240083172A (ko) * | 2021-08-04 | 2024-06-11 | 벤 바이오사이언시스 코포레이션 | 대장암 또는 진행성 선종 진단을 위한 바이오마커 |
WO2023019093A2 (en) * | 2021-08-07 | 2023-02-16 | Venn Biosciences Corporation | Detection of peptide structures for diagnosing and treating sepsis and covid |
CA3239488A1 (en) * | 2021-11-30 | 2023-06-08 | Daniel SERIE | Diagnosis of pancreatic cancer using targeted quantification of site-specific protein glycosylation |
WO2024059750A2 (en) * | 2022-09-16 | 2024-03-21 | Venn Biosciences Corporation | Diagnosis of ovarian cancer using targeted quantification of site-specific protein glycosylation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7776550B2 (en) | 2005-05-05 | 2010-08-17 | Philadelphia Health & Education Corporation | Diagnosis of liver pathology through assessment of protein glycosylation |
WO2009075883A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Georgia Research Foundation, Inc. | Glycoprotein cancer biomarker |
WO2009138392A1 (en) | 2008-05-14 | 2009-11-19 | ETH Zürich | Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith |
JP2012517607A (ja) | 2009-02-20 | 2012-08-02 | オンコノム,インコーポレイテッド | 大腸癌の診断及び予後判定のための用具セット及び方法 |
WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
US10534003B2 (en) | 2013-07-17 | 2020-01-14 | The Johns Hopkins University | Multi-protein biomarker assay for brain injury detection and outcome |
EP3676393A4 (en) | 2017-09-01 | 2021-10-13 | Venn Biosciences Corporation | IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT |
CN111479934A (zh) | 2017-10-18 | 2020-07-31 | 韦恩生物科技股份公司 | 用于诊断和治疗监测的生物学指标的鉴定和用途 |
-
2020
- 2020-01-31 KR KR1020217025999A patent/KR20210124269A/ko not_active Application Discontinuation
- 2020-01-31 AU AU2020216996A patent/AU2020216996A1/en active Pending
- 2020-01-31 JP JP2021544898A patent/JP7493815B2/ja active Active
- 2020-01-31 BR BR112021014978A patent/BR112021014978A2/pt unknown
- 2020-01-31 EP EP20709822.9A patent/EP3918334A1/en active Pending
- 2020-01-31 SG SG11202108327VA patent/SG11202108327VA/en unknown
- 2020-01-31 CA CA3128367A patent/CA3128367A1/en active Pending
- 2020-01-31 WO PCT/US2020/016286 patent/WO2020160515A1/en active Application Filing
- 2020-01-31 CN CN202080012122.6A patent/CN113439213A/zh active Pending
- 2020-01-31 US US17/433,971 patent/US20220139499A1/en active Pending
-
2021
- 2021-07-29 IL IL285218A patent/IL285218A/en unknown
- 2021-07-30 CL CL2021002013A patent/CL2021002013A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022524298A (ja) | 2022-05-02 |
CN113439213A (zh) | 2021-09-24 |
IL285218A (en) | 2021-09-30 |
CA3128367A1 (en) | 2020-08-06 |
SG11202108327VA (en) | 2021-08-30 |
WO2020160515A1 (en) | 2020-08-06 |
AU2020216996A1 (en) | 2021-09-16 |
KR20210124269A (ko) | 2021-10-14 |
US20220139499A1 (en) | 2022-05-05 |
BR112021014978A2 (pt) | 2022-01-04 |
EP3918334A1 (en) | 2021-12-08 |
JP7493815B2 (ja) | 2024-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002013A1 (es) | Biomarcadores para el diagnóstico de cáncer de ovario | |
MY202410A (en) | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring | |
MX2023011785A (es) | Metodos y composiciones para produccion de proteina de clara de huevo. | |
WO2016109813A3 (en) | Human pluripotent stem cell-based models for predictive developmental neural toxicity | |
BR112017018821A2 (pt) | métodos para quantificação de níveis de insulina através de espectrometria de massa | |
WO2018072862A8 (de) | Verfahren zum auswerten von daten einer massenspektrometrie und massenspektrometrisches verfahren sowie ein maldi tof massenspektrometer | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
BR112017015627A2 (pt) | Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm) | |
MX2019002918A (es) | Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. | |
MX2016016742A (es) | Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv). | |
BR112018015965A2 (pt) | método para determinação de helicobacter pylori | |
WO2017038702A8 (ja) | 蛍光x線分析装置 | |
EP3584166A3 (en) | Translucent illuminated evacuation slide | |
MX2019002929A (es) | Biomarcadores de arn para angioedema hereditario. | |
CY1125303T1 (el) | Meθοδοι γia thn aπολyth πoσotikoπoihσh πολυπεπτιδιων xamhλης aφθονιας me th xphσh φασματομετριας mazaς | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
EP3756014A4 (en) | TISSUE ANALYSIS BY MASS SPECTROMETRY | |
CO2022001531A2 (es) | Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc | |
EP3759469A4 (en) | CHAIN TEST DEVELOPMENT DIAGNOSIS ANALYSIS | |
EP4088219A4 (en) | MOTION CORRESPONDENCE ANALYSIS | |
WO2016012864A3 (en) | Biomarkers for anderson-fabry disease | |
CL2022002000A1 (es) | Biomarcadores para el diagnóstico del cáncer de ovario | |
WO2022246416A3 (en) | Biomarkers for diagnosing ovarian cancer | |
CO2019002599A2 (es) | Biomarcadores proteicos para enfermedades asociadas con el sistema de activación por contacto | |
CO2022009737A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso |